KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Receivables - Other: 2019-2023

Historic Receivables - Other for Royalty Pharma (RPRX) over the last 5 years, with Dec 2023 value amounting to $14.2 million.

  • Royalty Pharma's Receivables - Other fell 15.38% to $14.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $14.2 million, marking a year-over-year decrease of 15.38%. This contributed to the annual value of $14.2 million for FY2023, which is 15.38% down from last year.
  • Latest data reveals that Royalty Pharma reported Receivables - Other of $14.2 million as of FY2023, which was down 15.38% from $16.8 million recorded in FY2022.
  • Over the past 5 years, Royalty Pharma's Receivables - Other peaked at $53.3 million during FY2021, and registered a low of $14.2 million during FY2023.
  • In the last 3 years, Royalty Pharma's Receivables - Other had a median value of $16.8 million in 2022 and averaged $28.1 million.
  • Per our database at Business Quant, Royalty Pharma's Receivables - Other soared by 60.72% in 2021 and then crashed by 68.42% in 2022.
  • Yearly analysis of 5 years shows Royalty Pharma's Receivables - Other stood at $33.5 million in 2019, then declined by 1.10% to $33.2 million in 2020, then spiked by 60.72% to $53.3 million in 2021, then plummeted by 68.42% to $16.8 million in 2022, then dropped by 15.38% to $14.2 million in 2023.